期刊论文详细信息
Trials
Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial
Cheng-Shyong Chang3  Tsung-Chieh Lee4  Hung-Chang Chen2  Shou-Tung Chen1  Chia-Yun Chen5  Lun-Chien Lo5 
[1] Division of General Surgery, Department of Surgery, Changhua Christian Hospital, 135 Nanxiao St, Changhua City, Changhua Country, 500, Taiwan;Division of Colorectal Surgery, Department of Surgery, Changhua Christian Hospital, 135 Nanxiao St, Changhua City, Changhua Country, 500, Taiwan;Department of Hematology and Oncology, Changhua Christian Hospital, 135 Nanxiao St, Changhua City, Changhua Country, 500, Taiwan;Department of Chinese Medicine, Changhua Christian Hospital, 135 Nanxiao St, Changhua City, Changhua Country, 500, Taiwan;Department of Mathematics and Institute of Statistics and Information Science,National Changhua University of Education, No.1, Jin-De Road, Changhua City, Changhua Country, 500, Taiwan
关键词: Radiotherapy;    Chemotherapy;    Cancer;    Traditional Chinese Medicine;   
Others  :  1095096
DOI  :  10.1186/1745-6215-13-232
 received in 2012-06-15, accepted in 2012-11-14,  发布年份 2012
PDF
【 摘 要 】

Background

Cancer is one of the major health issues worldwide. An increasing number of cancer patients are offered treatment with surgery, chemotherapy and radiotherapy. Traditional Chinese medicine (TCM) is one of the most common complementary therapies offered to cancer patients in Taiwan. We designed a randomized,double-blind, placebo-controlled clinical trial to evaluate the efficacy of TCM in patients with cancer.

Methods/design

In this study, inclusion criteria are postoperative patients with histologically confirmed cancer within 3 years who are undergoing chemotherapy or radiotherapy, more than 18 years old, have given signed informed consent, have the ability to read Chinese, and the ability for oral intake.

Exclusion criteria include being pregnant, breast feeding, having completed chemotherapy or radiotherapy, brain metastasis with Eastern Cooperative Oncology Group (ECOG) performance status of two to four, delusion or hallucinations, acute infection, and have received medications under other clinical trials.

The patients were separated into an intervention group (Shen-Mai-San, SMS) and a placebo group for four weeks using a randomized, double-blind procedure. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QOL-C30) was used to evaluate the quality of life. General data, hemoglobin (Hb), hematocrit (Hct), glutamic-oxalacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), blood urea nitrogen (BUN), creatinine, carcinoembryonic antigen (CEA), TCM diagnosis data and heart rate variability (HRV) were also recorded. These data were collected at baseline, two weeks and four weeks after receiving medication. The patients were prescribed granules which contained therapeutic medicines or placebo. Paired-T test was used for statistical analysis.

Discussion

Shen-Mai-San is composed of processed Ginseng radis, Liriope spicata, and Schizandrae fructus. It was found to be effective for treating cancer-related fatigue and had anti-fatigue activity. In TCM theory, SMS has a synergistic effect for qi and yin deficiency and has the ability to prevent fatigue. The symptoms of qi and yin deficiency are similar to chemotherapy- or radiotherapy-induced side effects. In order to evaluate the efficacy of SMS on cancer treatment, we designed a randomized, double-blind, placebo-controlled trial.

Trial registration

This study is registered to Clinical Trails.gov NCT01580358

【 授权许可】

   
2012 Lo et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150130181343359.pdf 243KB PDF download
Figure 1. 69KB Image download
【 图 表 】

Figure 1.

【 参考文献 】
  • [1]Chen CJ, You SL, Lin LH, Hsu WL, Yang YW: Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 2002, 32(Suppl):S66-81.
  • [2]Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med 2008, 358:2482-2494.
  • [3]Valks R, Garcia-Diez A, Fernandez-Herrera J: Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 2000, 42:699.
  • [4]Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N: Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey Cancer Fatigue Forum. Ann Oncol 2000, 11:971-975.
  • [5]Gupta D, Lis CG, Grutsch JF: The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage 2007, 34:40-47.
  • [6]Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M: How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 2012, 11:187-203.
  • [7]Mao JJ, Palmer CS, Healy KE, Desai K, Amsterdam J: Complementary and alternative medicine use among cancer survivors: a population-based study. J Cancer Surviv 2011, 5:8-17.
  • [8]Lim CM, Ng A, Loh KS: Use of complementary and alternative medicine in head and neck cancer patients. J Laryngol Otol 2010, 124:529-532.
  • [9]Wyatt G, Sikorskii A, Wills CE, Su H: Complementary and alternative medicine use, spending, and quality of life in early stage breast cancer. Nurs Res 2010, 59:58-66.
  • [10]Sewitch MJ, Rajput Y: A literature review of complementary and alternative medicine use by colorectal cancer patients. Complement Ther Clin Pract 2010, 16:52-56.
  • [11]Chen YZ, Li ZD, Gao F, Zhang Y, Sun H, Li PP: Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer. Chin J Integr Med 2009, 15:415-419.
  • [12]Klafke N, Eliott JA, Wittert GA, Olver IN: Prevalence and predictors of complementary and alternative medicine (CAM) use by men in Australian cancer outpatient services. Ann Oncol 2012, 23:1571-1578.
  • [13]Chan KK, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY, Lau SK, Yip MW, Ngan HY: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 2011, 22:2241-2249.
  • [14]Liu ML, Chien LY, Tai CJ, Lin KC: Effectiveness of traditional Chinese medicine for liver protection and chemotherapy completion among cancer patients. Evid Based Complement Alternat Med 2011, 2011:291843.
  • [15]Guide Line of Clinical Trial of New Chinese Medicine http://www.ccmp.gov.tw/public/public.asp?selno=1254&relno=1254&level=C webcite.
  • [16]Zhang Y, Zheng H, Zhang Y, Zhang Y, Zhang Y: Zhang Yuansu yi xue quan shu. Beijing Shi: Zhongguo Zhong yi yao chu ban she; 2006.
  • [17]World Health Organization. Regional Office for the Western Pacific Region: WHO international standard terminologies on traditional medicine in the Western Pacific Region. Manila, Philippines: World Health Organization, Western Pacific Region; 2007.
  • [18]Liu P, Cao Y, Qiao X: Clinical study on shenmai injection in promoting postoperative recovery in patients of breast cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000, 20:328-329.
  • [19]Xu N, Qiu C, Wang W, Wang Y, Chai C, Yan Y, Zhu D: HPLC/MS/MS for quantification of two types of neurotransmitters in rat brain and application: myocardial ischemia and protection of Sheng-Mai-San. J Pharm Biomed Anal 2011, 55:101-108.
  • [20]Mok TS, Yeo W, Johnson PJ, Hui P, Ho WM, Lam KC, Xu M, Chak K, Chan A, Wong H, Mo F, Zee B: A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 2007, 18:768-774.
  • [21]Lee IY, Lee CC, Chang CK, Chien CH, Lin MT: Sheng mai san, a Chinese herbal medicine, protects against renal ischaemic injury during heat stroke in the rat. Clin Exp Pharmacol Physiol 2005, 32:742-748.
  • [22]Zhang F, Xu JX, Ma HG, Zhou LY, Cheng ZL: Sheng Mai Zhusheye improves the viability and movement parameters of human sperm in vitro. Zhonghua Nan Ke Xue 2009, 15:468-471.
  • [23]Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C, Duane S, Mattar B, Liu H, Atherton PJ, Christensen B, Loprinzi CL: Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 2010, 18:179-187.
  • [24]Wang J, Li S, Fan Y, Chen Y, Liu D, Cheng H, Gao X, Zhou Y: Anti-fatigue activity of the water-soluble polysaccharides isolated from Panax ginseng C A. Meyer. J Ethnopharmacol 2010, 130:421-423.
  • [25]Chen X, Bai X, Liu Y, Tian L, Zhou J, Zhou Q, Fang J, Chen J: Anti-diabetic effects of water extract and crude polysaccharides from tuberous root of Liriope spicata var. prolifera in mice. J Ethnopharmacol 2009, 122:205-209.
  • [26]Liu GT: Pharmacological actions and clinical use of fructus schizandrae. Chin Med J (Engl) 1989, 102:740-749.
  • [27]Lau KM, Lai KK, Liu CL, Tam JC, To MH, Kwok HF, Lau CP, Ko CH, Leung PC, Fung KP, Poon SK, Lau CB: Synergistic interaction between Astragali Radix and Rehmanniae Radix in a Chinese herbal formula to promote diabetic wound healing. J Ethnopharmacol 2012, 141:250-256.
  • [28]Zhang A, Sun H, Yuan Y, Sun W, Jiao G, Wang X: An in vivo analysis of the therapeutic and synergistic properties of Chinese medicinal formula Yin-Chen-Hao-Tang based on its active constituents. Fitoterapia 2011, 82:1160-1168.
  • [29]Shaohua Z, Ananda S, Ruxia Y, Liang R, Xiaorui C, Liang L: Fatal renal failure due to the Chinese herb "GuanMu Tong" (Aristolochia manshuriensis): autopsy findings and review of literature. Forensic Sci Int 2010, 199:e5-7.
  • [30]Takikawa H, Murata Y, Horiike N, Fukui H, Onji M: Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res 2009, 39:427-431.
  文献评价指标  
  下载次数:79次 浏览次数:11次